论文部分内容阅读
目的研究早期替罗非班对ST段抬高型心肌梗死PCI术患者预后的影响。方法选取2011年2月至2013年2月的80例ST段抬高型心肌梗死PCI术患者为研究对象,抽签随机分为观察组和对照组,每组40例。观察组在PCI手术前给予替罗非班,对照组在PCI手术后给予替罗非班。比较两组术后血浆N端B型利钠肽原(NT-pro BNP)、心肌肌钙蛋白I(c Tn I)水平变化,观察PCI后6个月的心脏不良事件及出血发生情况。结果两组术前NT-pro BNP与c Tn I含量比较差异未见统计学意义(P>0.05);术后5 d观察组NT-pro BNP水平为(1 758.25±198.5)ng/L,对照组为(2 144.8±214)ng/L,差异有统计学意义(P<0.05);观察组c Tn I水平为(21.4±5.2)mg/L,对照组为(30.7±10.9)mg/L,差异有统计学意义(P<0.05)。两组心脏不良事件及出血发生率比较差异未见统计学意义(P>0.05)。结论早期使用替罗非班用于ST段抬高型心肌梗死PCI术能减少患者心脏不良事件的发生率,降低出血风险,有利于预后的改善。
Objective To study the effect of early tirofiban on the prognosis of ST-segment elevation myocardial infarction patients undergoing PCI. Methods From February 2011 to February 2013, 80 patients with ST-elevation myocardial infarction were enrolled in the study. Randomly divided into observation group and control group, 40 patients in each group. The observation group was given tirofiban before PCI and the control group was given tirofiban after PCI. The levels of plasma NT-pro BNP and cTn I in the two groups were compared. The adverse cardiac events and bleeding were observed 6 months after PCI. Results There was no significant difference in preoperative NT-pro BNP and cTn I levels between the two groups (P> 0.05). The level of NT-pro BNP in the observation group was (1 758.25 ± 198.5) ng / L on the 5th postoperative day, (21.4 ± 5.2) mg / L in the observation group and (30.7 ± 10.9) mg / L in the control group (P <0.05). The level of cTnI in the observation group was (21.4 ± 5.2) , The difference was statistically significant (P <0.05). Two groups of cardiac adverse events and the incidence of bleeding was no significant difference (P> 0.05). Conclusion The early use of tirofiban in ST-segment elevation myocardial infarction can reduce the incidence of cardiac adverse events, reduce the risk of bleeding and improve prognosis.